Summary:
About 10–30% of patients with non-Hodgkin's lymphoma (NHL) intended to receive high-dose therapy are difficult to mobilise. Damage to the stem cell pool caused by previous chemotherapy may be an important factor in predicting progenitor cell mobilisation. We have analysed associations between chemotherapy score and efficiency of progenitor cell mobilisation in 120 consecutive NHL patients mobilised with intermediate-dose cyclophosphamide (4 g/m2) plus G-CSF. The original chemotherapy scoring system proposed by Drake et al was applicable in only 27% of our patients and was not predictive for mobilisation outcome. Therefore we made an improved scoring system for previous chemotherapy by adding new drugs. Altogether, 111 patients (93%) could be scored. Our chemotherapy score showed an inverse correlation with the peak blood CD34+ count measured after the mobilisation (r=−0.214, P=0.024) and with the number of CD34+ cells collected (r=−0.234, P=0.02). However, in the receiver operating characteristics curve, no threshold value could be detected for chemotherapy score predicting mobilisation failure. Thus, both the original scoring system as well as our more widely applicable scoring system seem to be of limited value in predicting progenitor cell mobilisation in patients with NHL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gratwohl A, Passweg J, Baldomero H et al. Hematopoietic stem cell transplant activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899–916.
Gratwohl A, Baldomero H, Horisberger B et al for The Accreditation Committee of The European Group for Blood and Marrow Transplantation (EBMT). Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100: 2374–2386.
Haas R, Möhle R, Fruhauf S et al. Patient characteristics associated with successful mobilization and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.
Drake M, Ranaghan L, Morris TCM et al. Analysis of the effect of prior chemotherapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–749.
Clark RE, Brammer CG . Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–863.
Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
Reiter A, Schrappe M, Parwaresh R et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage – a report of the Berlin–Frankfurt–Munster Group. J Clin Oncol 1995; 13: 359–372.
Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803–3809.
Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 873–878.
McQuaker I, Haynes A, Stainer C et al. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant 1999; 24: 715–722.
Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant–eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785.
Dormer P, Sauer H, Shalhorn A, Willmanns W . Differential effect of high-dose methotrexate on erythropoiesis and granulocytopoiesis in humans. Cancer Res 1982; 42: 1604–1697.
Guigon M, Izumi-Hisha H, Mary J-Y . Long-term effects of high-doses of cytosine arabinoside on pluripotents stem cells (CFU-S). Exp Hematol 1989; 17: 203–207.
Laszlo D, Galieni P, Raspadori D et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade lymphoma patients. Leuk Lymphoma 2000; 37: 157–161.
Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.
Koumakis G, Vassilomanolakis M, Hatzichristou H et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single aphaeresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065–1072.
Morton J, Morton A, Bird R et al. Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate-dose cyclophosphamide and G-CSF. Leukemia Res 1997; 21: 21–27.
Vantelon JM, Koscielny S, Brault P et al. Scoring system for the prediction of successful blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice. Bone Marrow Transplant 2000; 25: 495–499.
Neben S, Hemman S, Montgomery M et al. Haematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156–162.
Gardner RV, Lerner C, Astle CM, Harrison DE . Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol 1993; 32: 450–454.
Roberts AW, DeLuca E, Begley CG et al. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 1995; 13: 512–516.
Kessinger A, Sharp JG . The whys and hows of hematopoietic progenitor stem cell mobilization. Bone Marrow Transplant 2003; 31: 319–329.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jantunen, E., Kuittinen, T. & Nousiainen, T. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?. Bone Marrow Transplant 32, 569–573 (2003). https://doi.org/10.1038/sj.bmt.1704184
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704184
Keywords
This article is cited by
-
Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting
Indian Journal of Hematology and Blood Transfusion (2017)
-
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization
Bone Marrow Transplantation (2015)
-
Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo
Bone Marrow Transplantation (2012)
-
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma
Bone Marrow Transplantation (2004)
-
Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey
Bone Marrow Transplantation (2004)